All In Biotech

Drug Trial Radar · NCT03886246

Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study

Effisayil™ ON: An Open-label, Long Term Extension Study to Assess the Safety and Efficacy of Spesolimab Treatment in Patients With Generalized Pustular Psoriasis (GPP)

Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

131

Actual

Start

May 29, 2019

Primary completion

Sep 30, 2027

Study completion Apr 27, 2028

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
Collaborators
Boehringer Ingelheim
First posted
Mar 22, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to people with generalized pustular psoriasis (GPP). People can only take part if they have completed treatment in a previous study with spesolimab (1368-0013 or 1368-0027). The goal of this study is to find out how well people with GPP tolerate long-term treatment with spesolimab. The study also tests whether spesolimab helps improve GPP symptoms and how quickly the symptoms improve after a flare-up. Every participant gets spesolimab for almost 5 years (252 weeks). Depending on their symptoms and whether they had a GPP flare during the previous trial, they get spesolimab every few weeks. When participants have a GPP flare during this trial, they get spesolimab as an infusion into a vein. Participants visit their doctors regularly. During these visits, the doctors collect information on any health problems of the participants. To assess the study endpoints, doctors regularly check participants' skin.

Conditions

  • Generalized Pustular Psoriasis

Interventions

  • SpesolimabDrug

    Solution for infusion

  • SpesolimabDrug

    Solution for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of treatment emergent adverse events (TEAEs) up to week 252 of maintenance treatmentTime frame: Up to 252 Weeks

Locations

58 sites in 21 countries. Site status is shown where the registry gives one.

  • Oakland Hills Dermatology

    Auburn Hills, Michigan

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Hospital Italiano de Buenos Aires

    CABA, Argentina

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • Clínica Dermacross S.A.

    Vitacura, Chile

  • Sun yet-sen Memorial Hospital, Sun yet-sen Univesity

    Guangzhou, China

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, China

  • Shanghai Skin Disease Hospital

    Shanghai, China

  • Huashan Hospital, Fudan University

    Shanghai, China

  • Second Affiliated Hospital of Xi'an JiaoTong University

    Xi'an, China

  • HOP Saint-André

    Bordeaux, France

  • Hôpital de l'Archet

    Nice, France

  • HOP Saint-Louis

    Paris, France

  • HOP Robert Debré

    Reims, France

  • Fachklinik Bad Bentheim

    Bad Bentheim, Germany

  • Charité - Universitätsmedizin Berlin

    Berlin, Germany

  • Universitätsklinikum Bonn AöR

    Bonn, Germany

  • Universitätsklinikum Erlangen

    Erlangen, Germany

  • Universitätsklinikum Frankfurt

    Frankfurt am Main, Germany

  • Klinikum der Universität München - Campus Innenstadt

    München, Germany

  • Westfälische Wilhelms-Universität Münster

    Münster, Germany

  • Klinikum Oldenburg AöR

    Oldenburg, Germany

  • Istituto Clinico Humanitas

    Rozzano (MI), Italy

  • Nagoya City University Hospital

    Aichi, Nagoya, Japan

  • Tokyo Medical University Ibaraki Medical Center

    Ibaraki, Inashiki-gun, Japan

  • Saitama Medical University Hospital

    Saitama, Iruma-gun, Japan

  • Tokyo Medical University Hachioji Medical Center

    Tokyo, Hachioji, Japan

  • Hospital Pulau Pinang-Pulau Pinang-21953

    George Town, Malaysia

  • Hospital Raja Permaisuri Bainun

    Ipoh, Malaysia

  • Hospital Sultanah Aminah

    Johor Bahru, Malaysia

  • Hospital Sultan Ismail

    Johor Bahru, Malaysia

  • Queen Elizabeth Hospital

    Kota Kinabalu, Malaysia

  • Hospital Kuala Lumpur

    Kuala Lumpur, Malaysia

  • Hospital Selayang

    Kuala Selangor, Malaysia

  • Sarawak General Hospital

    Kuching, Sarawak, Malaysia

  • Hospital Pakar Sultanah Fatimah

    Muar town, Malaysia

  • Hospital Universitario Dr Jose Eleuterio Gonzalez

    Monterrey, Mexico

  • Southern Philippines Medical Center -Davao-62091

    Davao City, Philippines

  • Iloilo Doctors Hospital

    Iloilo City, Iloilo, Philippines

  • Zenith Skin Science Center Inc.

    Makati City, Philippines

Showing 40 of 58 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.